Literature DB >> 12072489

AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Simone Giannecchini1, Patrizia Isola, Olimpia Sichi, Donatella Matteucci, Mauro Pistello, Lucia Zaccaro, Daniela Del Mauro, Mauro Bendinelli.   

Abstract

Immunogenicity and protective activity of four cell-based feline immunodeficiency virus (FIV) vaccines prepared with autologous lymphoblasts were investigated. One vaccine was composed of FIV-infected cells that were paraformaldehyde fixed at the peak of viral expression. The other vaccines were attempts to maximize the expression of protective epitopes that might become exposed as a result of virion binding to cells and essentially consisted of cells mildly fixed after saturation of their surface with adsorbed, internally inactivated FIV particles. The levels of FIV-specific lymphoproliferation exhibited by the vaccinees were comparable to the ones previously observed in vaccine-protected cats, but antibodies were largely directed to cell-derived constituents rather than to truly viral epitopes and had very poor FIV-neutralizing activity. Moreover, under one condition of testing, some vaccine sera enhanced FIV replication in vitro. As a further limit, the vaccines proved inefficient at priming animals for anamnestic immune responses. Two months after completion of primary immunization, the animals were challenged with a low dose of homologous ex vivo FIV. Collectively, 8 of 20 vaccinees developed infection versus one of nine animals mock immunized with fixed uninfected autologous lymphoblasts. After a boosting and rechallenge with a higher virus dose, all remaining animals became infected, thus confirming their lack of protection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072489      PMCID: PMC136316          DOI: 10.1128/jvi.76.14.6882-6892.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women.

Authors:  Y Wang; L Tao; E Mitchell; C Bravery; P Berlingieri; P Armstrong; R Vaughan; J Underwood; T Lehner
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

2.  AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; P Isola; A Merico; L Zaccaro; A Rizzuti; M Bendinelli
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

Review 3.  Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections.

Authors:  J H Elder; T R Phillips
Journal:  Adv Virus Res       Date:  1995       Impact factor: 9.937

4.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; L Zaccaro; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Temperature dependence of cell-cell fusion induced by the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  S Frey; M Marsh; S Günther; A Pelchen-Matthews; P Stephens; S Ortlepp; T Stegmann
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

6.  Suppression of feline immunodeficiency virus replication in vitro by a soluble factor secreted by CD8+ T lymphocytes.

Authors:  J N Flynn; C A Cannon; D Sloan; J C Neil; O Jarrett
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

7.  Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication.

Authors:  H F Egberink; E De Clercq; A L Van Vliet; J Balzarini; G J Bridger; G Henson; M C Horzinek; D Schols
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.

Authors:  L S Laube; M Burrascano; C E Dejesus; B D Howard; M A Johnson; W T Lee; A E Lynn; G Peters; G S Ronlov; K S Townsend
Journal:  Hum Gene Ther       Date:  1994-07       Impact factor: 5.695

10.  Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.

Authors:  C Y Kang; K Hariharan; P L Nara; J Sodroski; J P Moore
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more
  17 in total

1.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.

Authors:  Giulia Freer; Donatella Matteucci; Paola Mazzetti; Francesca Tarabella; Valentina Catalucci; Enrica Ricci; Antonio Merico; Leonia Bozzacco; Mauro Pistello; Mauro Bendinelli
Journal:  Clin Vaccine Immunol       Date:  2008-01-23

3.  Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Authors:  Mauro Pistello; Francesca Bonci; Elisa Zabogli; Francesca Conti; Giulia Freer; Fabrizio Maggi; Mario Stevenson; Mauro Bendinelli
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

4.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

5.  Prior mucosal exposure to heterologous cells alters the pathogenesis of cell-associated mucosal feline immunodeficiency virus challenge.

Authors:  Surender B Kumar; Sarah Leavell; Kyle Porter; Barnabe D Assogba; Mary J Burkhard
Journal:  Retrovirology       Date:  2010-05-28       Impact factor: 4.602

6.  Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity.

Authors:  Simone Giannecchini; Anna Maria D'Ursi; Cinzia Esposito; Mario Scrima; Elisa Zabogli; Giulia Freer; Paolo Rovero; Mauro Bendinelli
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

7.  Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.

Authors:  Simone Giannecchini; Armida Di Fenza; Anna Maria D'Ursi; Donatella Matteucci; Paolo Rovero; Mauro Bendinelli
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

8.  Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Authors:  Suzanne Willey; Marlén M I Aasa-Chapman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Robin A Weiss; Stuart J D Neil
Journal:  Retrovirology       Date:  2011-03-14       Impact factor: 4.602

Review 9.  Feline immunodeficiency virus (FIV) neutralization: a review.

Authors:  Margaret J Hosie; Daniela Pajek; Ayman Samman; Brian J Willett
Journal:  Viruses       Date:  2011-10-13       Impact factor: 5.048

10.  Time-course analysis of main markers of primary infection in cats with the feline immunodeficiency virus.

Authors:  B Ribba; H El Garch; S Brunet; E Grenier; F Castiglione; H Poulet; P Vanhems
Journal:  Comput Math Methods Med       Date:  2012-09-25       Impact factor: 2.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.